Investors purchased shares of Intellia Therapeutics Inc (NASDAQ:NTLA) on weakness during trading on Wednesday. $6.86 million flowed into the stock on the tick-up and $3.93 million flowed out of the stock on the tick-down, for a money net flow of $2.93 million into the stock. Of all stocks tracked, Intellia Therapeutics had the 25th highest net in-flow for the day. Intellia Therapeutics traded down ($0.58) for the day and closed at $18.70

Several equities research analysts recently commented on NTLA shares. Zacks Investment Research upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Wedbush restated an “outperform” rating and issued a $38.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, August 23rd. Leerink Swann assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price target on the stock. Credit Suisse Group AG assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price target on the stock. Finally, Jefferies Group restated a “buy” rating and issued a $33.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, August 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Intellia Therapeutics presently has an average rating of “Buy” and an average price target of $35.50.

The company’s market cap is $673.11 million. The stock’s 50-day moving average price is $20.17 and its 200-day moving average price is $22.46.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/traders-buy-shares-of-intellia-therapeutics-inc-ntla-on-weakness.html

Several hedge funds and other institutional investors have recently bought and sold shares of NTLA. FMR LLC acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $112,182,000. Temasek Holdings Private Ltd acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $16,878,000. BlackRock Advisors LLC acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $13,146,000. Vanguard Group Inc. acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $8,894,000. Finally, Franklin Resources Inc. acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $6,405,000.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

5 Day Chart for NASDAQ:NTLA

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.